NAD+ depletion radiosensitizes 2-DG-treated glioma cells by abolishing metabolic adaptation

Xiaolin Shi,Wei Zhang,Cheng Gu,Huangge Ren,Chen Wang,Narui Yin,Zhongmin Wang,Jiahua Yu,Fenju Liu,Haowen Zhang

DOI: https://doi.org/10.1016/j.freeradbiomed.2020.11.007

IF: 8.101

2021-01-01

Free Radical Biology and Medicine

Abstract:Two-deoxy-d-glucose (2-DG) mediated glucose restriction (GR) has been applied as a potential therapeutic strategy for tumor clinical treatments. However, increasing evidences have indicated that 2-DG alone is inefficient in killing tumor cells, and the effect of 2-DG on modifying tumor radio-responses also remains controversial. In this study, we found that 2-DG triggered metabolic adaption in U87 glioma cells by up-regulating nicotinamide phosphoribosyltransferase (NAMPT) and cellular NAD+ content, which abolished 2-DG-induced potential radiosensitizing effect in glioma cells. Strikingly, NAD+ depletion evoked notable oxidative stress by NADPH reduction and hence re-radiosensitized 2-DG-treated glioma cells. Furthermore, isocitrate dehydrogenase-1 (IDH1) mutant U87 glioma cells with deficiency in the rate-limiting enzyme of Preiss‐Handler pathway nicotinate phosphoribosyltransferase (Naprt1) revealed notable 2-DG-induced oxidative stress and radiosensitization. Our findings implied that targeting NAD+ could radiosensitize gliomas with GR, and 2-DG administration could be benefit for tumor patients with IDH1 mutation.

biochemistry & molecular biology,endocrinology & metabolism

What problem does this paper attempt to address?

The problems that this paper attempts to solve are: the radiosensitizing effect of 2 - DG (2 - deoxy - D - glucose) in glioma cells and its mechanism. Specifically, the research aims to explore the following issues: 1. **Whether 2 - DG can enhance the sensitivity of glioma cells to radiotherapy**: Although 2 - DG, as a potential metabolic inhibitor, is used clinically for the treatment of malignant tumors, the effects of its use alone or in combination with radiotherapy are controversial. Studies have shown that 2 - DG may protect cells from oxidative stress damage by triggering metabolic adaptation, thereby weakening its radiosensitizing effect. 2. **The role of NAD+ in glioma cells treated with 2 - DG**: The study found that after 2 - DG treatment, the NAD+ level in U87 glioma cells increased, which may be achieved by up - regulating NAMPT (nicotinamide phosphoribosyltransferase). As an important coenzyme, NAD+ plays a key role in DNA damage repair, energy metabolism, and oxidative - stress - induced cell death. 3. **Whether NAD+ depletion can re - enhance the sensitivity of glioma cells treated with 2 - DG to radiotherapy**: By inhibiting NAMPT expression or blocking the classical NAD+ salvage pathway, the research team found that NAD+ depletion can significantly increase the sensitivity of glioma cells treated with 2 - DG to radiotherapy, which is mainly achieved by reducing NADPH levels and increasing oxidative stress. 4. **The impact of IDH1 mutation on the radiosensitivity of glioma cells**: Glioma cells carrying the IDH1 R132H mutation exhibit lower NAD+ and NADPH levels, leading to higher oxidative stress and radiosensitivity. The study also showed that 2 - DG pretreatment significantly enhanced the radiosensitivity of these mutant cells. ### Main Conclusions - Using 2 - DG alone cannot effectively enhance the sensitivity of glioma cells to radiotherapy. Instead, it may trigger metabolic adaptation by up - regulating NAMPT and NAD+ levels, reducing the cell's sensitivity to oxidative stress. - NAD+ depletion can re - enhance the sensitivity of glioma cells treated with 2 - DG to radiotherapy by reducing NADPH levels and increasing oxidative stress. - Glioma cells carrying the IDH1 R132H mutation show higher radiosensitivity due to lower NAD+ and NADPH levels, and 2 - DG pretreatment further enhances this sensitivity. - These findings provide a theoretical basis for potential metabolic therapies targeting NAD+ metabolism, especially for glioma cells tolerant to glucose restriction and patients carrying IDH1 mutations. ### Formula Presentation - The classical salvage synthesis pathway of NAD+: \[ \text{NAM} + 5'-\text{PRPP} \xrightarrow{\text{NAMPT}} \text{NMN} + \text{PPi} \] \[ \text{NMN} \xrightarrow{\text{NMNAT}} \text{NAD}^+ \] - Changes in ATP levels: \[ \Delta [\text{ATP}] = [\text{ATP}]_{\text{final}} - [\text{ATP}]_{\text{initial}} \] - Measurement of ROS levels: \[ \text{DCF fluorescence intensity} \propto [\text{ROS}] \] These formulas show the basic principles of NAD+ synthesis pathways, changes in ATP levels, and measurement of ROS levels, which are helpful for understanding the experimental design and result analysis in the paper.

NAD+ depletion radiosensitizes 2-DG-treated glioma cells by abolishing metabolic adaptation

Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists

2-Deoxy-D-glucose increases the sensitivity of glioblastoma cells to BCNU through the regulation of glycolysis, ROS and ERS pathways: In vitro and in vivo validation

Abstract 2037: Enhanced chemosensitivity to DNA-damaging agents in human high-grade glioma through 2-DG treatment

α-Ketoglutarate supplementation and NAD+ modulation enhance metabolic rewiring and radiosensitization in SLC25A1 inhibited cancer cells

Differential mechanisms of radiosensitization by 2-deoxy-D-glucose in the monolayers and multicellular spheroids of a human glioma cell line

Targeting Glioblastoma Stem Cells with 2-Deoxy-D-Glucose (2-DG) Potentiates Radiation-Induced Unfolded Protein Response (UPR)

Targeting Glucose Metabolism of Cancer Cells with Dichloroacetate to Radiosensitize High-Grade Gliomas

Distinct Capabilities in NAD Metabolism Mediate Resistance to NAMPT Inhibition in Glioblastoma

Enhancement of radiation and chemotherapeutic drug responses by 2-deoxy-D-glucose in animal tumors

Glioblastoma Sensitization to Therapeutic Effects by Glutamine Deprivation Depends on Cellular Phenotype and Metabolism

Apigenin sensitizes radiotherapy of mouse subcutaneous glioma through attenuations of cell stemness and DNA damage repair by inhibiting NF-κB/HIF-1α-mediated glycolysis

2-Deoxyglucose treatment complements the cisplatin- or BH3-only mimetic-induced suppression of neuroblastoma cell growth

The nitric oxide donor JS-K sensitizes U87 glioma cells to repetitive irradiation

Ndrg2 Is A Novel P53-Associated Regulator Of Apoptosis In C6-Originated Astrocytes Exposed To Oxygen-Glucose Deprivation

Gelsolin knockdown confers radiosensitivity to glioblastoma cells

Tmic-79. Idh1-R132H Rewires Autophagy In The Glioma Microenvironment To Facilitate Tumor Progression And Response To Radiation

DNA-PKcs Deficiency Inhibits Glioblastoma Cell-Derived Angiogenesis after Ionizing Radiation.

Knockdown of NF-E2-related Factor 2 Inhibits the Proliferation and Growth of U251MG Human Glioma Cells in a Mouse Xenograft Model

Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice

Exploiting Metabolic Defects in Glioma with Nanoparticle Encapsulated NAMPT Inhibitors